Related Experiment Videos
Naproxen sodium decreases migraine recurrence when administered with sumatriptan
1Headache Center of Rio de Janeiro, Brasil. abouchkrym@openlink.com.br
Arquivos De Neuro-Psiquiatria
|August 2, 2000
Summary
Sumatriptan is often followed by migraine recurrence. Combining sumatriptan with naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID), significantly reduced migraine recurrence in clinical studies.
Area of Science:
- Neurology
- Pharmacology
Background:
- Sumatriptan is a common acute migraine treatment.
- Migraine recurrence after sumatriptan treatment affects 40-78% of patients.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended to reduce recurrence.
Purpose of the Study:
- To evaluate the efficacy of combining sumatriptan with naproxen sodium in reducing migraine recurrence.
- To compare the recurrence rates of sumatriptan alone versus sumatriptan plus naproxen sodium.
Main Methods:
- Prospective study of 67 patients with high sumatriptan recurrence rates.
- Patients treated 4 attacks with sumatriptan (100 mg) plus naproxen sodium (550 mg).
- Double-blind, randomized trial comparing sumatriptan plus naproxen sodium versus sumatriptan plus placebo in 26 patients over 3 attacks each.
Main Results:
- Initial combination therapy reduced recurrence from 62.5% to 14.2% (p<0.0001).
- In the double-blind phase, sumatriptan plus naproxen sodium recurrence was 25.5% compared to 59% for sumatriptan plus placebo (p<0.0003).
Conclusions:
- Combination therapy with sumatriptan and naproxen sodium significantly decreases migraine recurrence.
- This combination offers an effective strategy for managing patients experiencing recurrent migraines after sumatriptan treatment.